BR112013000529A2 - compostos espiro-heterocíclicos inéditos como antagonistas mglu5 - Google Patents

compostos espiro-heterocíclicos inéditos como antagonistas mglu5

Info

Publication number
BR112013000529A2
BR112013000529A2 BR112013000529A BR112013000529A BR112013000529A2 BR 112013000529 A2 BR112013000529 A2 BR 112013000529A2 BR 112013000529 A BR112013000529 A BR 112013000529A BR 112013000529 A BR112013000529 A BR 112013000529A BR 112013000529 A2 BR112013000529 A2 BR 112013000529A2
Authority
BR
Brazil
Prior art keywords
treatment
compounds
mglu5
disorder
disorders
Prior art date
Application number
BR112013000529A
Other languages
English (en)
Other versions
BR112013000529B1 (pt
Inventor
Amedeo Leonardi
Carlo Riva
Carlo De Toma
Davide Graziani
Gianni Motta
Katia Dimitrova Karamfilova
Luciano Guarneri
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of BR112013000529A2 publication Critical patent/BR112013000529A2/pt
Publication of BR112013000529B1 publication Critical patent/BR112013000529B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

compostos espiro-ehetrocíclicos inéditos como antagonistas mglu5. a invenção diz respeito a compostos com a fórmula geral i em que x é o ou s; r1 é c,n,o ou s; r1a é ch, ch2, n ou nh: r2 é um ligação, ch ou ch2; é 1,2 ou 3; n é 1 ou 2; quando n é 2 ou m é 2ou 3, o anel contendo r1 pode ser fundido com um anel de benzeno; cada - representa uma ligação única ou dupla desde que uma ligação dupla se estenda do átomo de carbono no qual r3-c=c - é ligado e que nenhum átomo de carbono do anel carregue duas ligações duplas; e r3, r4 e r5 representem uma ampla faixa de substituintes. esses compostos são seletivos para o receptor metabotrópico de mglu5. eles, seus solvatos, gidratos, enantiômetros, diastereômeros, n-óxidos e sais farmceuticamente aceitáveis, e composições farmacêuticas contendo-os, podem ser usados para tratar doenças ou dist´rubios do trato urinário inferior, especialmente disfunções neuromusculares do trato urinário inferior. eles podem também ser usados pra o tratamento de enxaqueca; para o tratamento de doença de refluxo gastroesófagico (gerd); para o tratamento de distúrbio de ansiedade; para o tratamento de abuso, dependência de substância e distúrbio da retirada da substância; para o tratamento de distúrbio de dor neuropática; e para o tratamento de distúrbios da síndrome do x frágil.
BR112013000529-7A 2010-07-09 2011-07-08 compostos espiro-heterocíclicos como antagonistas mglu5 e composição farmacêutica contendo ditos compostos BR112013000529B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36294410P 2010-07-09 2010-07-09
PCT/EP2011/061690 WO2012004400A1 (en) 2010-07-09 2011-07-08 Novel spiroheterocyclic compounds as mglu5 antagonists

Publications (2)

Publication Number Publication Date
BR112013000529A2 true BR112013000529A2 (pt) 2016-05-24
BR112013000529B1 BR112013000529B1 (pt) 2019-11-19

Family

ID=44503767

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013000529-7A BR112013000529B1 (pt) 2010-07-09 2011-07-08 compostos espiro-heterocíclicos como antagonistas mglu5 e composição farmacêutica contendo ditos compostos

Country Status (17)

Country Link
US (1) US8580962B2 (pt)
EP (1) EP2590985B1 (pt)
JP (1) JP2013529673A (pt)
KR (1) KR101862626B1 (pt)
CN (1) CN103097391B (pt)
AU (1) AU2011275696B2 (pt)
BR (1) BR112013000529B1 (pt)
CA (1) CA2800930C (pt)
EA (1) EA023020B1 (pt)
ES (1) ES2492694T3 (pt)
HK (1) HK1179248A1 (pt)
IL (1) IL223330A (pt)
MX (1) MX2013000300A (pt)
NZ (1) NZ603868A (pt)
SG (1) SG186107A1 (pt)
UA (1) UA110343C2 (pt)
WO (1) WO2012004400A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113223C2 (xx) * 2012-08-13 2016-12-26 Арилетинілпіримідини
US9593127B2 (en) * 2014-12-29 2017-03-14 Recordati Ireland Ltd. Heterocyclylalkyne derivatives and their use as modulators of mGluR5 receptors
KR102035048B1 (ko) 2015-06-03 2019-10-22 에프. 호프만-라 로슈 아게 에틴일 유도체
CN107903265A (zh) * 2017-11-21 2018-04-13 毛琳琳 一种新型螺环类杀虫剂的制备方法及应用
CN116351472A (zh) * 2023-02-22 2023-06-30 万华化学集团股份有限公司 一种催化精馏生产异氰酸酯的制备方法和系统

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW593241B (en) 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
US6548522B1 (en) * 1999-10-12 2003-04-15 Hoffmann-La Roche Inc. Method for treating conditions related to the glutamate receptor using carboxylic acid amide derivatives
SV2002000205A (es) 1999-11-01 2002-06-07 Lilly Co Eli Compuestos farmaceuticos ref. x-01095
PT1294358E (pt) 2000-06-28 2004-12-31 Smithkline Beecham Plc Processo de moagem por via humida
US6369222B1 (en) 2000-07-18 2002-04-09 Hoffmann-La Roche Inc. mGluR antagonists and a method for their synthesis
GB0322612D0 (en) * 2003-09-26 2003-10-29 Novartis Ag Organic compounds
GB0508318D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
WO2008032191A2 (en) * 2006-09-13 2008-03-20 Astrazeneca Ab Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators

Also Published As

Publication number Publication date
JP2013529673A (ja) 2013-07-22
EA201270799A1 (ru) 2013-05-30
MX2013000300A (es) 2013-02-27
SG186107A1 (en) 2013-01-30
CN103097391B (zh) 2015-04-08
NZ603868A (en) 2014-08-29
EA023020B1 (ru) 2016-04-29
CA2800930C (en) 2018-08-21
US8580962B2 (en) 2013-11-12
IL223330A (en) 2015-09-24
AU2011275696B2 (en) 2016-02-11
CA2800930A1 (en) 2012-01-12
UA110343C2 (en) 2015-12-25
US20120059015A1 (en) 2012-03-08
ES2492694T3 (es) 2014-09-10
CN103097391A (zh) 2013-05-08
WO2012004400A1 (en) 2012-01-12
KR101862626B1 (ko) 2018-05-31
EP2590985A1 (en) 2013-05-15
BR112013000529B1 (pt) 2019-11-19
KR20130097153A (ko) 2013-09-02
HK1179248A1 (en) 2013-09-27
EP2590985B1 (en) 2014-05-14
IL223330A0 (en) 2013-02-03
AU2011275696A1 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
AU2009237649B2 (en) Indole modulators of the alpha 7 nicotinic acetylcholine receptor
CY1121601T1 (el) Ενωσεις διαμιδιου που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα 2 αδρενεργικου υποδοχεα
DE602005008558D1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen
UY29421A1 (es) Nuevos compuestos de n-(n-sulfonilaminoarilmetil) ciclopropanocarboxanida sustituidos, comoposiciones farmacéuticas que los contienen a aplicaciones.
BR112013000529A2 (pt) compostos espiro-heterocíclicos inéditos como antagonistas mglu5
NO20064579L (no) Bifenylforbindelser anvendelige som muskariniske receptorantagonister
UA99620C2 (en) Pyridyl piperidine orexin receptor antagonists
DOP2006000046A (es) Derivados de oxindol
BR112015015812A2 (pt) derivados de pirimidina fundidos a pirido ou pirrolo como inibidores de autotaxina para tratamento de dor
CY1108880T1 (el) Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα
CY1112601T1 (el) Υποκατεστημενα παραγωγα 1-πιπεριδιν-4-υλ-4-πυρρολιδιν-3-υλ-πιπεραζινης και χρηση αυτων ως ανταγωνιστων νευροκινινης
MX2007011848A (es) Antagonistas del receptor de procineticina i.
TW200716566A (en) Prokineticin 2 receptor antagonists
EA201001645A1 (ru) Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
MX2009005541A (es) Indoles que actuan como antagonistas del receptor v1a.
HRP20050554B1 (hr) Supstituirani 1- piperidin-3-il-4-piperidin-4-il-piperazinski derivati i njihova primjena kao neurokininskih antagonista
NO20063562L (no) Fusjonerte heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
EA200501594A1 (ru) Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора
Fiorino et al. New 5-HT1A receptor ligands containing a N′-cyanoisonicotinamidine nucleus: Synthesis and in vitro pharmacological evaluation
EA201071227A1 (ru) (5r)-1,5-диарил-4,5-дигидро-1h-пиразол-3-карбоксамидиновые производные, обладающие св1-антагонистической активностью
BRPI0816971A2 (pt) Derivados de piperidina como antagonistas de receptor nk3
JP2008532968A (ja) ＧｌｙＴ１阻害薬としてのピペラジン誘導体
BRPI0812253A2 (pt) Derivados de prolinamida-tetrazol como antagonistas do receptor nk-3
UA99521C2 (ru) Хинуклидин-производные как антагонисты мускариновых рецепторов м3
UA89846C2 (ru) Производные карбоксамида как антагонисты мускариновых рецепторов

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2011, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2011, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2678 DE 03-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.